Arbutus Biopharma Corp - Common Shares, without par value (ABUS)

Historical Holders from Q2 2015 to Q1 2025

Symbol
ABUS on Nasdaq
CUSIP
03879J100
Type / Class
Equity / Common Shares, without par value
Shares outstanding
189M
All holders as of December 31, 2024
Q4 2024
Shares, excl. options
104M
Holdings value
$341M
% of all portfolios
0.004%
Grand Portfolio weight change
+0%
Number of holders
153
Number of buys
68
Number of sells
-54
Average Value change %
0%
Average buys %
+0%
Average sells %
-0.001%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Arbutus Biopharma Corp - Common Shares, without par value (ABUS)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Roivant Sciences Ltd. 20.5% $129M 38.8M Roivant Sciences Ltd. Feb 21, 2025
MORGAN STANLEY 11.4% $71.2M 21.5M Morgan Stanley Dec 31, 2024
Whitefort Capital Management, LP 7% $44M 13.3M Whitefort Capital Master Fund, LP Feb 20, 2025

Institutional Holders of Arbutus Biopharma Corp - Common Shares, without par value (ABUS)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q1 262K $916K -$16.5K $3.49 7
2024 Q4 104M $341M +$3.79M $3.27 153
2024 Q3 101M $388M +$15.5M $3.85 142
2024 Q2 96.4M $297M +$40.9M $3.09 128
2024 Q1 83M $214M +$6.78M $2.58 118
2023 Q4 78.6M $196M +$6.61M $2.50 106
2023 Q3 70.8M $144M +$8.05M $2.03 94
2023 Q2 66.2M $152M +$7.4M $2.30 107
2023 Q1 62M $188M +$26.5M $3.03 116
2022 Q4 53.7M $125M +$17.7M $2.33 106
2022 Q3 46.3M $88.6M +$2.67M $1.91 115
2022 Q2 43.9M $119M +$1.78M $2.71 97
2022 Q1 43.8M $130M +$4.15M $2.98 106
2021 Q4 38.9M $151M +$14.6M $3.89 111
2021 Q3 34.9M $150M +$25.4M $4.29 96
2021 Q2 28.9M $87.6M +$8.19M $3.03 82
2021 Q1 26M $86.4M +$11.9M $3.33 87
2020 Q4 21.9M $77.7M -$4.92M $3.55 70
2020 Q3 21.9M $68.5M +$7.51M $3.13 56
2020 Q2 26.1M $47.6M +$964K $1.82 45
2020 Q1 23.6M $23.9M -$13.5M $1.01 38
2019 Q4 24M $66.8M +$11.8M $2.78 47
2019 Q3 17.6M $26.9M -$3.35M $1.53 41
2019 Q2 21.1M $44M -$10.5M $2.08 53
2019 Q1 24.1M $86.2M -$442K $3.58 63
2018 Q4 24.1M $92.4M -$11.1M $3.83 62
2018 Q3 24M $227M +$17.7M $9.45 83
2018 Q2 20.4M $149M +$30.1M $7.30 64
2018 Q1 18.4M $91.9M -$79.6M $5.00 43
2017 Q4 34.2M $173M +$4.99M $5.05 48
2017 Q3 31.1M $193M -$1.1M $6.20 48
2017 Q2 36.9M $133M +$3.19M $3.60 43
2017 Q1 31M $101M +$962K $3.25 46
2016 Q4 35.9M $88.2M +$3.85M $2.45 51
2016 Q3 33.4M $115M +$54.7M $3.44 46
2016 Q2 17.4M $60.5M -$710K $3.48 46
2016 Q1 17.5M $72.4M -$3.36M $4.13 45
2015 Q4 18.4M $81.7M -$100M $4.45 46
2015 Q3 34.9M $212M +$211M $6.09 51
2015 Q2 207K $2.46M +$2.46M $11.86 1